Lisata extends tender offer deadline to May 29; Kuva to pay up to $1.1M in expenses

LISATA THERAPEUTICS, INC.

Tender offer commencement extended from April 13 to May 29, 2026, under amended merger agreement.
Kuva Labs to pay Lisata up to $1.1M via five interim payments: $175k on May 5, $175k on May 7, $250k on May 12, $250k on May 19, $250k on May 26.
Lisata agrees not to sue Kuva until May 29; waives all claims for failure to start offer by April 13 upon commencement and payment of interim amounts.
Waiver terminates if Kuva fails to make any interim payment when due or commits an uncured material breach.
Original merger agreement signed March 6, 2026; deal remains subject to regulatory and stockholder conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LISATA THERAPEUTICS, INC. amended Amendment and Waiver with Kuva Labs Inc. and Kuva Acquisition Corp. valued at up to $1.1 million (effective 2026-05-03).

Action: amendment
Agreement: merger
Counterparty: Kuva Labs Inc. and Kuva Acquisition Corp.
Value: up to $1.1 million
Effective: 2026-05-03

Exact text from the filing

On May 3, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment and waiver (the “Amendment and Waiver”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (the “Merger Agreement”).

View on SEC.gov

Browse all material agreements →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-018651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.